Epidemiology and Antifungal Susceptibilities of Yeasts Causing Vulvovaginitis in a Teaching Hospital

Mycopathologia

Volumn 178, Issue 3-4, 2014, Pages 251-258

  Gamarra, Soledad ^a   Morano, Susana ^b   Dudiuk, Catiana ^a   Mancilla, Estefanía ^a,c   Nardin, María Elena ^b   de los Angeles Méndez, Emilce ^b   Garcia Effron, Guillermo ^a  

^a UNIVERSIDAD NACIONAL DEL LITORAL   (Argentina)

^b Hospital Jose M Cullen   (Argentina)

^c Hospital San Carlos Casilda   (Argentina)

Author keywords

Identification; Susceptibility; Vulvovaginitis; Yeast

Indexed keywords

ANTIFUNGAL AGENT;

ADOLESCENT; ADULT; ANIMAL; CANDIDA; CANDIDIASIS, VULVOVAGINAL; CLASSIFICATION; DRUG EFFECTS; FEMALE; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PREGNANCY; RISK FACTOR; SACCHAROMYCES CEREVISIAE; TEACHING HOSPITAL; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, VULVOVAGINAL; FEMALE; HOSPITALS, TEACHING; HUMANS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PREGNANCY; RISK FACTORS; SACCHAROMYCES CEREVISIAE; YOUNG ADULT;

EID: 84929516408     PISSN: 0301486X     EISSN: 15730832     Source Type: Journal    
DOI: 10.1007/s11046-014-9780-2     Document Type: Article

References (52)

1. Sobel JD. Vulvovaginitis. When Candida becomes a problem. Dermatol Clin 1998;16:763–8, xii.
2. Nyirjesy P, Sobel JD. Vulvovaginal candidiasis. Obstet Gynecol Clin North Am. 2003;30:671–84.
3. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503–35.
4. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007;20:133–63.
5. Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis. 2003;37:634–43.
6. Lockhart SR, Messer SA, Gherna M, et al. Identification of Candida nivariensis and Candida bracarensis in a large global collection of Candida glabrata isolates: comparison to the literature. J Clin Microbiol. 2009;47:1216–7.
7. Diekema DJ, Messer SA, Boyken LB, et al. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J Clin Microbiol. 2009;47:3170–7.
8. Bauters TG, Dhont MA, Temmerman MI, Nelis HJ. Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol. 2002;187:569–74.
9. Holland J, Young ML, Lee O, Chen A. Vulvovaginal carriage of yeasts other than Candida albicans. Sex Transm Infect. 2003;79:249–50.
10. Mathema B, Cross E, Dun E, et al. Prevalence of vaginal colonization by drug-resistant Candida species in college-age women with previous exposure to over-the-counter azole antifungals. Clin Infect Dis. 2001;33:E23–7.
11. Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D, et al. Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: results from population-based surveillance of candidemia in Spain. Antimicrob Agents Chemother. 2008;52:1506–9.
12. Lachance MA, Boekhout T, Scorzetti G, Fell JW, Kurtzman CP. The yeasts a taxonomic study. London. Editorial: Elsevier; 2013.
13. Staib P, Morschhauser J. Chlamydospore formation in Candida albicans and Candida dubliniensis an enigmatic developmental programme. Mycoses. 2007;50:1–12.
14. Khan ZU, Ahmad S, Mokaddas E, Chandy R. Tobacco agar, a new medium for differentiating Candida dubliniensis from Candida albicans. J Clin Microbiol. 2004;42:4796–8.
15. Slifkin M. Tween 80 opacity test responses of various Candida species. J Clin Microbiol. 2000;38:4626–8.
16. Alves SH, Milan EP, de Laet SP, Oliveira LO, Santurio JM, Colombo AL. Hypertonic sabouraud broth as a simple and powerful test for Candida dubliniensis screening. Diagn Microbiol Infect Dis. 2002;43:85–6.
17. Donnelly SM, Sullivan DJ, Shanley DB, Coleman DC. Phylogenetic analysis and rapid identification of Candida dubliniensis based on analysis of ACT1 intron and exon sequences. Microbiology. 1999;145(Pt 8):1871–82.
18. White TJ, Bruns TD, Lee SB, Taylor JW. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics. In: Innis MA, Gelfand DH, Sninsky JJ, White TJ, editors. PCR protocols: a guide to methods and applications. San Diego, Calif: Academic press, Inc.; 1990. p. 315–22.
19. Romeo O, Criseo G. First molecular method for discriminating between Candida africana, Candida albicans, and Candida dubliniensis by using HPW1 gene. Diagn Microbiol Infect Dis. 2008;62:230–3.
20. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press; 1998.
21. Echeverria-Irigoyen MJ, Eraso E, Cano J, Gomariz M, Guarro J, Quindos G. Saccharomyces cerevisiae vaginitis: microbiology and in vitro antifungal susceptibility. Mycopathologia. 2011;172:201–5.
22. Haynes KA, Westerneng TJ. Rapid identification of Candida albicans, C. glabrata, C. parapsilosis and C. krusei by species-specific PCR of large subunit ribosomal DNA. J Med Microbiol. 1996;44:390–6.
23. Li YL, Leaw SN, Chen JH, Chang HC, Chang TC. Rapid identification of yeasts commonly found in positive blood cultures by amplification of the internal transcribed spacer regions 1 and 2. Eur J Clin Microbiol Infect Dis. 2003;22:693–6.
24. Garcia-Effron G, Canton E, Peman J, Dilger A, Roma E, Perlin DS. Assessment of two new molecular methods for identification of Candida parapsilosis sensu lato species. J Clin Microbiol. 2011;49:3257–61.
25. Enache-Angoulvant A, Guitard J, Grenouillet F, et al. Rapid discrimination between Candida glabrata, Candida nivariensis, and Candida bracarensis by use of a singleplex PCR. J Clin Microbiol. 2011;49:3375–9.
26. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts. Third edition. Document M27-A3. 2008.
27. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast: fourth informational supplement—CLSI document M27-S4-Wayne, PA. 2012.
28. Sobel JD, Faro S, Force RW, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178:203–11.
29. Ilkit M, Guzel AB. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective. Crit Rev Microbiol. 2011;37:250–61.
30. Xu J, Schwartz K, Bartoces M, Monsur J, Severson RK, Sobel JD. Effect of antibiotics on vulvovaginal candidiasis: a MetroNet study. J Am Board Fam Med. 2008;21:261–8.
31. Sobel JD. Management of recurrent vulvovaginal candidiasis: unresolved issues. Curr Infect Dis Rep. 2006;8:481–6.
32. Blignaut E, Messer S, Hollis RJ, Pfaller MA. Antifungal susceptibility of South African oral yeast isolates from HIV/AIDS patients and healthy individuals. Diagn Microbiol Infect Dis. 2002;44:169–74.
33. Vermitsky JP, Self MJ, Chadwick SG, et al. Survey of vaginal-flora Candida species isolates from women of different age groups by use of species-specific PCR detection. J Clin Microbiol. 2008;46:1501–3.
34. Spinillo A, Capuzzo E, Gulminetti R, Marone P, Colonna L, Piazzi G. Prevalence of and risk factors for fungal vaginitis caused by non-albicans species. Am J Obstet Gynecol. 1997;176:138–41.
35. Saporiti AM, Gomez D, Levalle S, et al. Vaginal candidiasis: etiology and sensitivity profile to antifungal agents in clinical use. Rev Argent Microbiol. 2001;33:217–22.
36. Richter SS, Galask RP, Messer SA, Hollis RJ, Diekema DJ, Pfaller MA. Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol. 2005;43:2155–62.
37. Mujica MT, Finquelievich JL, Jewtuchowicz V, Iovannitti CA. Prevalence of Candida albicans and Candida non-albicans in clinical samples during 1999–2001. Rev Argent Microbiol. 2004;36:107–12.
38. Giusiano G, Rojas F, Toma-Vanacore S, Mangiaterra M. Frequency and antifungal profile of Candida isolated from vaginal exudates of preadolescent girls. Enferm Infecc Microbiol Clin. 2009;27:428.
39. Garcia HM, Garcia SD, Copolillo EF, et al. Prevalence of vaginal candidiasis in pregnant women. Identification of yeasts and susceptibility to antifungal agents. Rev Argent Microbiol. 2006;38:9–12.
40. Corsello S, Spinillo A, Osnengo G, et al. An epidemiological survey of vulvovaginal candidiasis in Italy. Eur J Obstet Gynecol Reprod Biol. 2003;110:66–72.
41. Buscemi L, Arechavala A, Negroni R. Study of acute vulvovaginitis in sexually active adult women, with special reference to candidosis, in patients of the Francisco J. Muniz Infectious Diseases Hospital. Rev Iberoam Micol. 2004;21:177–81.
42. Arechavala AI, Bianchi MH, Robles AM, Santiso G, Negroni R. Identification and susceptibility against fluconazole and albaconazole of 100 yeasts’ strains isolated from vaginal discharge. Rev Iberoam Micol. 2007;24:305–8.
43. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med. 1991;91:72S–5S.
44. Paulitsch A, Weger W, Ginter-Hanselmayer G, Marth E, Buzina W. A 5-year (2000–2004) epidemiological survey of Candida and non-Candida yeast species causing vulvovaginal candidiasis in Graz, Austria. Mycoses. 2006;49:471–5.
45. Kalkanci A, Guzel AB, Khalil II, Aydin M, Ilkit M, Kustimur S. Yeast vaginitis during pregnancy: susceptibility testing of 13 antifungal drugs and boric acid and the detection of four virulence factors. Med Mycol. 2012;50:585–93.
46. Borman AM, Szekely A, Linton CJ, Palmer MD, Brown P, Johnson EM. Epidemiology, antifungal susceptibility, and pathogenicity of Candida africana isolates from the United Kingdom. J Clin Microbiol. 2013;51:967–72.
47. Cross EW, Park S, Perlin DS. Cross-Resistance of clinical isolates of Candida albicans and Candida glabrata to over-the-counter azoles used in the treatment of vaginitis. Microb Drug Resist. 2000;6:155–61.
48. Ribeiro MA, Dietze R, Paula CR, Da Matta DA, Colombo AL. Susceptibility profile of vaginal yeast isolates from Brazil. Mycopathologia. 2001;151:5–10.
49. Sobel JD, Wiesenfeld HC, Martens M, et al. Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med. 2004;351:876–83.
50. Guitard J, Angoulvant A, Letscher-Bru V, et al. Invasive infections due to Candida norvegensis and Candida inconspicua: report of 12 cases and review of the literature. Med Mycol. 2013;51(8):795–799.
51. Arikan S, Ostrosky-Zeichner L, Lozano-Chiu M, et al. In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. J Clin Microbiol. 2002;40:1406–12.
52. Carrillo-Munoz AJ, Quindos G, Tur C, et al. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole. J Antimicrob Chemother. 1999;44:397–401.